Nattokinase for Health & Longevity - Quick Reference Sheet

Nattokinase for Health & Longevity

Created on 10/15/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Gemini 4 Argon – Audit

Nattokinase is an oral dietary supplement containing a protein-splitting enzyme from fermented soybeans used to support healthy blood pressure and blood flow. Standard daily doses modestly lower blood pressure in adults with elevated blood pressure, but do not slow neck artery thickening or improve cholesterol when blood pressure is normal. Higher-dose artery-plaque findings remain unconfirmed, and bleeding risks require verified, vitamin K-free extracts without blood-thinning medications. (Full Review)

Protocol

Standard antihypertensive regimen
2,000 FU (100 mg) orally once daily
Single daily capsule for baseline blood pressure ≥130/85 mmHg; matches EU Novel Food daily limit
Competing high-dose vascular regimens
6,000–10,800 FU/day orally
Divided into 2 or 3 daily doses in carotid plaque, hyperlipidemia, or cerebrovascular stenosis studies
Best time of day
Evening or post-dinner (empty stomach)
Aligns peak serum levels (~13.3 hours post-dose) with the morning PAI-1 and platelet surge
Time to effect
Blood pressure reductions
4–8 weeks
At 2,000 FU/day in adults with elevated baseline blood pressure (≥130/85 mmHg)
Carotid plaque protocols
6–12 months
High-dose plaque protocols (6,000–10,800 FU/day) and 6-month cognitive trial (8,000 FU/day)
Acute fibrinolytic shifts
2–8 hours
Transient D-dimer elevation, factor VIII reduction, and aPTT prolongation after 2,000 FU

Benefits

Contraindications
  • Individuals with active internal bleeding, coagulopathy (hemophilia, von Willebrand disease), or prior intracranial hemorrhage/cerebral microbleeds
  • Patients scheduled for upcoming surgery or invasive procedures
  • Individuals with confirmed allergy to fermented soybeans (natto) or soy protein
  • Pregnant and lactating women, and individuals under 18 years
Key Interactions
  • Prescription Anticoagulants (warfarin, apixaban, rivaroxaban, dabigatran, enoxaparin)
  • Prescription Antiplatelet Medications (clopidogrel, prasugrel, ticagrelor, dipyridamole; theoretical for P2Y12 inhibitors)
  • Over-the-Counter Antiplatelets and Nonsteroidal Anti-Inflammatory Drugs (aspirin, ibuprofen, naproxen)
  • Prescription Antihypertensive Medications (lisinopril, losartan, amlodipine, hydrochlorothiazide; theoretical)
  • Anticoagulant and Proteolytic Supplements (omega-3 fish oil, Ginkgo biloba, garlic, vitamin E, serrapeptase, bromelain; theoretical)
  • Additive Cardiovascular Supplements (red yeast rice, Pycnogenol)
  • Vitamin K2-Rich Foods and Supplements (whole fermented natto, menaquinone-7; theoretical)

Risk & Side Effects

  • High:
  • Medium:
  • Low: Major hemorrhage; mechanical heart valve thrombosis when substituted for warfarin; systemic anaphylaxis and hypersensitivity in soy or natto allergy; upper-extremity vascular necrosis from intravenous self-injection; small increases in LDL cholesterol, total cholesterol, and fasting glucose
  • Speculative: Symptomatic hypotension in normotensive or hypotensive adults; opportunistic bacteremia from unpurified Bacillus subtilis var. natto spores

Monitoring

Marker Target Why
Seated Resting Blood Pressure <120/80 mmHg (standard reference range) Expected-change efficacy marker (and safety check for hypotension <90/60 mmHg)
Activated Partial Thromboplastin Time (aPTT) and Prothrombin Time / INR (PT/INR) 25–35 seconds for aPTT; 0.8–1.1 for INR (standard reference range) Safety check to rule out supratherapeutic anticoagulation (and acute pharmacodynamic marker)
Plasma Fibrinogen and Coagulation Factor VIII Activity 200–400 mg/dL for fibrinogen; 50%–150% for factor VIII (standard reference range) Expected-change marker of fibrinolytic and anticoagulant response
Fasting Lipid Panel (LDL Cholesterol, HDL Cholesterol, Total Cholesterol) and Fasting Glucose <100 mg/dL for LDL, ≥40 mg/dL (men) or ≥50 mg/dL (women) for HDL, <200 mg/dL for total cholesterol; 70–99 mg/dL for fasting glucose (standard reference range) Safety check for short-term lipid or glucose shifts and expected-change efficacy marker at ≥6,000 FU/day
Carotid Duplex Ultrasound (IMT and Plaque Area) No established target; track stabilization or regression from individual baseline Expected-change efficacy marker when targeting subclinical atherosclerosis with high doses

Cadence: Baseline testing before initiation; seated home blood pressure weekly for 8 weeks then monthly; coagulation markers at 4 to 8 weeks (when using >2,000 FU/day); fasting lipids and glucose at 3 to 6 months; carotid duplex ultrasound every 6 to 12 months.

Qualitative Assessment

  • Unexplained bruising, petechiae (pinpoint skin bleeds), or gingival (gum) bleeding: Early signs of excessive hemostatic activity.
  • Orthostatic lightheadedness upon standing: Indicator of excessive blood pressure lowering.
  • Epistaxis (nosebleeds), hematuria (blood in urine), or melena (dark tarry stools): Red-flag bleeding signs.